Cooper Companies’ (COO) “Neutral” Rating Reiterated at Bank of America

Bank of America reaffirmed their neutral rating on shares of Cooper Companies (NASDAQ:COO) in a report released on Thursday, MarketBeat reports. The brokerage currently has a $65.00 price target on the medical device company’s stock, down from their prior price target of $80.00.

COO has been the topic of several other research reports. Piper Sandler downgraded shares of Cooper Companies from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $86.00 to $59.00 in a research note on Thursday. Needham & Company LLC lowered their price objective on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Wells Fargo & Company reissued a “sell” rating and issued a $66.00 price objective (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a research report on Wednesday, May 27th. Finally, BNP Paribas Exane dropped their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, June 8th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Cooper Companies currently has a consensus rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Stock Down 0.5%

Shares of NASDAQ:COO opened at $53.91 on Thursday. Cooper Companies has a 1 year low of $51.01 and a 1 year high of $89.83. The business has a 50 day simple moving average of $71.62 and a two-hundred day simple moving average of $69.70. The firm has a market capitalization of $10.25 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts predict that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies announced that its board has approved a share repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

Large investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC increased its holdings in shares of Cooper Companies by 290.4% during the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after acquiring an additional 25,504 shares in the last quarter. Tidal Investments LLC boosted its stake in Cooper Companies by 281.4% in the 2nd quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock worth $5,945,000 after purchasing an additional 61,165 shares in the last quarter. National Pension Service boosted its stake in Cooper Companies by 9,314.0% in the 2nd quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock worth $37,730,000 after purchasing an additional 520,560 shares in the last quarter. WINTON GROUP Ltd grew its position in Cooper Companies by 379.0% during the 2nd quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company’s stock worth $3,046,000 after purchasing an additional 33,613 shares during the last quarter. Finally, Engineers Gate Manager LP grew its position in Cooper Companies by 8,637.7% during the 2nd quarter. Engineers Gate Manager LP now owns 249,897 shares of the medical device company’s stock worth $17,920,000 after purchasing an additional 247,037 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.